RBC Capital analyst Gregory Renza maintained a Buy rating on Verastem (VSTM – Research Report) yesterday and set a price target of $32.00. The company’s shares closed yesterday at $11.92.
According to TipRanks, Renza is a 5-star analyst with an average return of 18.7% and a 47.62% success rate. Renza covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, Agios Pharma, and Alpine Immune Sciences.
Verastem has an analyst consensus of Strong Buy, with a price target consensus of $28.13, a 135.99% upside from current levels. In a report released yesterday, BTIG also maintained a Buy rating on the stock with a $27.00 price target.
The company has a one-year high of $15.18 and a one-year low of $4.68. Currently, Verastem has an average volume of 137.7K.
Based on the recent corporate insider activity of 26 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of VSTM in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Verastem (VSTM) Company Description:
Verastem, Inc., operating as Verastem Oncology, is a biopharmaceutical company focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA™ (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. The indication in FL is approved under accelerated approval based on overall response rate. In addition, it is developing the focal adhesion kinase inhibitor defactinib, which is being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), and mesothelioma. Verastem, Inc. has collaboration agreements with Yakult Honsha Co., Ltd., CSPS Pharmaceutical Group Limited and The Leukemia & Lymphoma Society. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.
Read More on VSTM:
